vestichИзвестия Национальной академии наук Беларуси. Серия химических наукProceedings of the National Academy of Sciences of Belarus, Chemical Series1561-83312524-2342The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"vestich-273Research ArticleБИООРГАНИЧЕСКАЯ ХИМИЯBIOORGANIC CHEMISTRYБЕЛКОВОЕ ПРОФИЛИРОВАНИЕ КЛЕТОК HepG2 С ИСПОЛЬЗОВАНИЕМ «SHOTGUN» ПРОТЕОМИКИ КАК МЕТОД, ПРИМЕНИМЫЙ ДЛЯ ИССЛЕДОВАНИЯ БИОПТАТОВSHOTGUN PROTEOMIC PROFILING OF HepG2 CELL LINE AS A METHOD APPLICABLE FOR BIOPSY SPECIMEN ANALYSISСтанишевскийС. Б.StanisheuskiS. B.

магистр хим. наук, мл. науч. сотрудник

M. Sc. (Chemistry), Junior researcher

Stanislau.Stanisheuski@gmail.comИванчикА. В.IvanchykA. V.

аспирант, мл. науч. сотрудник

Ph. D. student, Junior researcher

AlexIvan4ik@gmail.comШапироМ. А.ShapiraM. A.

магистр биол. наук, мл. науч. сотрудник

M. Sc. (Biology), Junior researcher

MShapira2016@gmail.comЯнцевичА. В.YantsevichA. V.

канд. хим. наук, зав. лаб.

Ph. D. (Chemistry), Head of Laboratory

Al.Yantsevich@gmail.comСысаА. Г.SysaA. G.

канд. хим. наук, ст. науч. сотрудник

Ph. D. (Chemistry), Senior researcher

Aliaksei.Sysa@gmail.comИнститут биоорганической химии НАН БеларусиInstitute of Bioorganic Chemistry of the National Academy of Sciences of Belarus201707102017037984Copyright © Станишевский С.Б., Иванчик А.В., Шапиро М.А., Янцевич А.В., Сыса А.Г., 20172017Станишевский С.Б., Иванчик А.В., Шапиро М.А., Янцевич А.В., Сыса А.Г.Stanisheuski S.B., Ivanchyk A.V., Shapira M.A., Yantsevich A.V., Sysa A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestichem.belnauka.by/jour/article/view/273

Описаны результаты применения «Shotgun» протеомного подхода в анализе микрограммовых количеств биологического материала с целью идентификации специфических белковых маркеров в клеточной линии высокодифференцированной гепатоцеллюлярной карциномы HepG2.

 

The results of shotgun proteomic analysis of microgram quantities of hepatocellular carcinoma cells (HepG2) are described. Identified is a number of proteins which have been reported to be biomarkers and therapy targets.

«Shotgun» протеомикаHepG2белковое профилирование биомаркерыбелки-мишениshotgun proteomicsHepG2proteomic profilingbiomarkerstherapy targetsReferencesQuantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors / H. Bohnenberger [et al.] // J. of Visualized Experiments. – 2015. – Vol. 96. – P. 52435.Bohnenberger H., Ströbel P., Mohr S., Corso J., Berg T., Urlaub H., Lenz C., Serve H., Oellerich T., “Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors”, Journal of Visualized Experiments, 2015, vol. 96, p. 52435.Feist, P. Proteomic Challenges: Sample Preparation Techniques for Microgram-Quantity Protein Analysis from Biological Samples / Р. Feist, А. В. Hummon // International Journal of Molecular Sciences. – 2015. – Vol. 16(2). – P. 3537–3563.Feist Р., Hummon А. В., “Proteomic Challenges: Sample Preparation Techniques for Microgram-Quantity Protein Analysis from Biological Samples”, International Journal of Molecular Sciences, 2015, vol. 16(2), pp. 3537–3563.Оптимизация проведения отдельных стадий пробоподготовки в протеомном анализе /А.В. Иванчик [и др.] // Сб. науч. ст. Первого Белорусского биохимического конгресса. – Гродно: ЮрСаПринт, 2016. – Ч. 2. – С. 169–174.Ivanchyk A. V., Shapira M. A., Shchur V. V., Iantsevich A. V., “Optimization of separate stages of sample preparation in proteomic analysis”, Sovremennye problemy biokhimii : sbornik nauchnykh statei I Belorusskogo biokhimicheskogo kongressa, Grodno, 5–6 iiulia 2016 g. : v 2 chastiakh, Nadol’nik L. I. (gl. red.), Grodno, 2016 [Modern problems of biochemistry: a collection of scientific articles of the I Belorussian Biochemical Congress, Grodno, July 5–6, 2016: in 2 parts, Nadolnik L. I. (ed.), Grodno, 2016], IurSaPrint, Grodno, BY, 2016, part 2, pp. 169–174.HepG2 (liver hepatocellular carcinoma): cell culture and transfection protocol // [Электронный ресурс]. – Режим доступа: http://www.hepg2.com. Дата доступа: 10.11.16.“HepG2 (liver hepatocellular carcinoma): cell culture and transfection protocol”, Available at: http://www.hepg2.com, (accessed 10.11.16).Heat shock proteins HSP27, HSP60, HSP70, and HSP90 expression in bladder carcinoma / Т. Lebret [et al.] // Cancer. – 2003. – Vol. 98(5). – P. 970–977.Lebret T., Watson R. W., Molinié V., O’Neill A., Gabriel C., Fitzpatrick J. M., Botto H., “Heat shock proteins HSP27, HSP60, HSP70, and HSP90 expression in bladder carcinoma”, Cancer, 2003, vol. 98(5), pp. 970–977.Proteomic Characterization of Annexin l (ANX1) and Heat Shock Protein 27 (HSP27) as Biomarkers for Invasive Hepatocellular Carcinoma Cells / Ruo-Chiau Wang [et al.] // Journal Pone. – 2015. – Vol. 10. – P. 2–10.Wang R. C., Huang C. Y., Pan T. L., Chen W. Y., Ho C. T., Liu T. Z., Chang Y. J., “Proteomic Characterization of Annexin l (ANX1) and Heat Shock Protein 27 (HSP27) as Biomarkers for Invasive Hepatocellular Carcinoma Cells”, PLoS One, 2015, vol. 10, pp. 2–10.Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells. / P. Nirdé [et al.] // Oncogene. – 2010. – Vol. 29. – P. 117–127.Nirde P., Derocq D., Maynadier M., Chambon M., Basile I., Gary-Bobo M., Garcia1 M., “Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells”, Oncogene, 2010, vol. 29, pp. 117–127.Prodrugs from serendipity to rational design / К. М. Huttunen [et al.] // Pharmacological Reviews. – 2011. – Vol. 63 (3). – Р. 750–761.Huttunen K. M., Raunio H., Rautio J., “Prodrugs from serendipity to rational design”, Pharmacological Reviews, 2011, vol. 63 (3), pp. 750–761.Pinto, N. Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy / N. Pinto // Pharmacogenomics. – 2009. – Vol. 10. – P. 1897–1903.Pinto N., “Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy”, Pharmacogenomics, 2009, vol. 10, pp. 1897–1903.14-3-3ζ positive expression is associated with a poor prognosis in patients with glioblastoma. / X. Yang [et al.] // Neurosurgery. – 2011. – Vol. 68(4). – P. 932–938.Yang X., Cao W., Zhou J., Zhang W., Zhang X., Lin W., Fei Z., Lin H., Wang B., “14-3-3 zeta positive expression is associated with a poor prognosis in patients with glioblastoma”, Neurosurgery, 2011, vol. 68 (4), pp. 932–938.

The authors declare that there are no conflicts of interest present.